Quick Answer
VYNE Therapeutics Inc. reported Common Stock Shares Outstanding of 33.32 million shares for the year ending 2025.
- VYNE Therapeutics Inc. showed an increase of +124.7% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: 22.98 million shares | Q2 2018: 22.98 million shares | Q3 2018: 23.23 million shares | Q1 2019: 23.67 million shares | Q2 2019: 23.94 million shares | Q3 2019: 23.98 million shares | Q1 2020: 61.50 million shares | Q2 2020: 167.68 million shares | Q3 2020: 167.86 million shares | Q1 2021: 51.39 million shares | Q2 2021: 51.51 million shares | Q3 2021: 53.51 million shares | Q1 2022: 57.91 million shares | Q2 2022: 58.01 million shares | Q3 2022: 58.04 million shares | Q1 2023: 3.27 million shares | Q2 2023: 3.28 million shares | Q3 2023: 3.30 million shares | Q1 2024: 14.30 million shares | Q2 2024: 14.54 million shares | Q3 2024: 14.75 million shares | Q1 2025: 15.96 million shares | Q2 2025: 19.77 million shares.
- Over the full 10 years of available data (2016 to 2025), VYNE Therapeutics Inc.'s Common Stock Shares Outstanding has grown by 531.1%.
- Historical annual values: Fiscal year 2025: 33.32 million shares | Fiscal year 2024: 14.83 million shares | Fiscal year 2023: 14.10 million shares | Fiscal year 2022: 3.23 million shares | Fiscal year 2021: 2.98 million shares | Fiscal year 2020: 43.21 million shares | Fiscal year 2019: 9.12 million shares | Fiscal year 2018: 23.23 million shares | Fiscal year 2017: 5.30 million shares | Fiscal year 2016: 5.28 million shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: